Corpus Intelligence IC Memo — HOSPITAL MENONITA CAGUAS INC 2026-04-26 08:03 UTC
IC Memo — HOSPITAL MENONITA CAGUAS INC
Investment Committee Memorandum | PR | 232 beds | Grade C | EBITDA uplift $8.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOSPITAL MENONITA CAGUAS INC

CCN 400104 | nan, PR | 232 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HOSPITAL MENONITA CAGUAS INC is a 232-bed safety-net/medicaid heavy in nan, PR with $114.1M in net patient revenue and a 6.8% operating margin. The hospital serves a payer mix of 8.7% Medicare, 30.6% Medicaid, and 60.7% commercial.

Thesis: Platform Growth. Our ML models identify $8.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 6.8% to 14.1% (+736bps).

Net Revenue HCRIS$114.1M
Current EBITDA COMPUTED$7.7M
Operating Margin COMPUTED6.8%
Occupancy HCRIS75.5%
Revenue / Bed COMPUTED$492K
Net-to-Gross HCRIS77.3%
Distress Probability ML54.8%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
34
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of 6.8% places it above the state median. Among 34 size-comparable peers (116-464 beds), the median margin is -8.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (116-464), prioritizing same-state peers. 34 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOSPITAL MENONITA CAGUAS INC (Target)PR232$114.1M6.8%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
SAN LUCAS PONCEPR348$141.1M9.2%
HOSPITAL DR. ALEJANDRO OTEROPR263$129.0M-1.0%
HOSPITAL HIMA SAN PABLO CAGUASPR421$120.1M-23.4%
DOCTOR CENTER HOSPITAL MANATI PR258$103.4M1.6%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.4M+210bp18mo
Cost to Collect4.5%2.5%$2.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.4M+122bp9mo
Clean Claim Rate88.0%96.0%$73K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.4M
Cost to Collect
$2.3M
Denial Rate Reduction
$2.3M
A/R Days Reduction
$1.4M
Clean Claim Rate
$73K
Total EBITDA Uplift$8.4M
Current EBITDA$7.7M
+ RCM Uplift+$8.4M
Pro Forma EBITDA$16.1M
Current Margin6.8%
Pro Forma Margin14.1%
WC Released (1x)$4.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$11.9M$134.8M11.37x62.6%
Base (11x exit)10.0x11.0x$11.9M$152.1M12.83x66.6%
Bull Case9.0x11.0x$10.7M$183.7M17.22x76.7%
Bull (12x exit)9.0x12.0x$10.7M$203.6M19.08x80.3%
Bear Case11.0x10.0x$13.0M$89.0M6.82x46.8%
Bear (11x exit)11.0x11.0x$13.0M$102.1M7.83x50.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (30.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 54.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 34 hospitals with 116-464 beds
  • Same-state prioritization (n=35)
  • Comp margins: P25=-20.4% / P50=-8.2% / P75=1.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.